A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Treatment and outcomes of chronic coronary syndromes: the EORP EURECA imaging registry

Tekijät: Liga, Riccardo; Gimelli, Alessia; Podlesnikar, Tomaz; Cvijic, Marta; Pontone, Gianluca; Miglioranza, Marcelo Haertel; Guaricci, Andrea Igoren; Seitun, Sara; Clemente, Alberto; Sumin, Alexey; Vitola, Joao; Saraste, Antti; Paunonen, Christian; Sia, Ching-Hui; Paleev, Filipp; Sade, Leyla Elif; Zamorano, Jose Luis; Maroz-Vadalazhskaya, Natallia; Sredojevic, Mirjana; Anagnostopoulos, Constantinos; Macedo, Filipe; Knuuti, Juhani; Edvardsen, Thor; Cosyns, Bernard; Petersen, Steffen E.; Magne, Julien; Laroche, Cecile; Popescu, Bogdan A.; Delgado, Victoria; Neglia, Danilo; EURECA Investigators

Kustantaja: Oxford University Press (OUP)

Julkaisuvuosi: 2025

Lehti:: European Heart Journal

Artikkelin numero: ehaf594

Vuosikerta: 46

Numero: 39

Aloitussivu: 3922

Lopetussivu: 3927

ISSN: 0195-668X

eISSN: 1522-9645

DOI: https://doi.org/10.1093/eurheartj/ehaf594

Verkko-osoite: https://doi.org/10.1093/eurheartj/ehaf594

Julkaisussa olevat rahoitustiedot: 
Since the start of EORP, the following companies have supported the programme: Abbott Vascular (2011–2021), Amgen (2009–2018), AstraZeneca France (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific Corporation (2009–2012), Bristol-Myers Squibb and Pfizer (2011–2019), Daiichi Sankyo Europe (2011–2020), The Daiichi Sankyo Europe and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter (2014–2016), Menarini Group (2009–2012), Merck Sharp and Dohme France (2011–2014), Novartis Pharma (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), Servier (2009–2018), Vifor Pharma (2019–2022).